Fig. 3From: Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trialsAveraged treatment effect comparing mepolizumab 75 mg versus placebo in severe asthma across quintiles of predicted treatment benefit. Left panel, observed treatment benefit in terms of average reduction in the rate of severe exacerbations per year; Right panel, observed treatment benefit in terms of average reduction in ACQ5 scoresBack to article page